Skip to content
LIVE
The Executives BriefThe Executives Brief

NAD+ flips the off switch on the enzyme that erases immune memory

A Science Immunology study shows how innate immune cells stay primed for weeks or months, and why that mechanism could matter for cancer, aging and vaccines never designed for the diseases they prevent.

ByYousef Al-ZahraniTechnology Correspondent, The Executives Brief
·4 min read
NAD+ flips the off switch on the enzyme that erases immune memory
Executive summary

A study published Oct. 30 in Science Immunology reports that the molecule NAD+ latches onto KDM5a, the enzyme that erases innate immune cells' epigenetic memory, and shuts it down without being consumed, keeping those cells primed for rapid inflammation. For drug developers and longevity investors, it offers a concrete, testable link between metabolism and immune memory, while the study's thin human data argues against treating NAD+ as a dial to simply turn up.

The immune system has a memory eraser, and a new study shows what jams it. The eraser is an enzyme called KDM5a. The jammer is a molecule called nicotinamide adenine dinucleotide, or NAD+, which has long been known to help regulate how DNA gets packaged inside cells. According to research published Oct. 30 in the journal Science Immunology, NAD+ latches onto KDM5a and shuts it down, as if pushing an "off" button. The twist is what NAD+ does not do: it is not consumed in the process. Enzymes normally burn through NAD+ to run chemical reactions. Here, the molecule binds, survives, and keeps the eraser disabled, which is precisely what allows a form of immune memory to persist.

That answers a question immunologists had left open. The immune system's first line of defense, innate immune cells such as macrophages, can be flipped into an activated, primed state so they are ready the moment they meet a germ. The phenomenon is called "trained immunity," and it broadly sharpens the cells' defenses, letting them respond faster and harder than untrained cells would. The switch is epigenetic, meaning it changes how genes are used without altering the underlying DNA code. DNA is typically wound around tiny spools inside cells, and gene activity depends on how tightly or loosely it is wound. Epigenetic markers grab those spools and tweak the winding, activating or silencing genes. In this case, a molecule latches onto the spool near genes involved in sparking inflammation. That subtle tweak "holds those genes poised for rapid activation," said Musa Mhlanga, a cell biologist and molecular geneticist at the Radboud Institute for Molecular Life Sciences in the Netherlands, who was not involved in the new study.

The problem was durability. The mark should have been wiped out almost as soon as it was made. As Mhlanga put it to Live Science in an email, "the cell has enzymes whose entire job is to strip that mark off." Yet the memory stuck. "So the obvious question was never really answered: how does a mark survive weeks or months against machinery actively removing it?" he said. The new paper's answer runs through metabolism. Past studies hinted that when immune cells enter their primed state, their metabolism shifts, driving up NAD+ production. The new work shows NAD+ then takes on an unexpected role: instead of being spent, it disables KDM5a, the enzyme that would otherwise erase the memory. Restrain the eraser, and the cell stays primed and ready to ignite inflammation when triggered.

The experiments spanned mouse immune cells, live lab mice and some human cells in lab dishes. When researchers reduced or eliminated NAD+ from immune cells, the cells failed to enter the primed state. In mice with cancer, that hobbled the immune system's ability to attack tumor cells. In aging mice, the team observed NAD+ levels dwindling in step with the innate immune system's ability to respond to threats. Mhlanga called the work a convincing "molecular bridge" between those two observations, and said it raises a hypothesis for why immunity gets worse with age.

The implications reach beyond the lab bench. This line of research may help explain "why some vaccines protect against diseases they were never designed for," Mhlanga said. The classic example is Bacille Calmette-Guerin, or BCG, the tuberculosis vaccine thought to mount a broad immune response that may help stave off conditions ranging from viral infections to Alzheimer's disease. Some scientists think Alzheimer's stems from a dysregulated immune response that BCG may help normalize. Cancer and Alzheimer's are both named in the study as diseases where this understanding might eventually matter for treatment.

Then come the caveats, and they matter for anyone tempted to over-read the result. The researchers ran a few experiments with human cells and backed up some mouse findings with data from human cancer patients, but "the human data are thin by comparison with the mouse work," Mhlanga noted, so they need further confirmation. He said he would be interested in future studies exploring NAD+ in the aging immune system, cancer and Alzheimer's disease. The research hints that pushing NAD+ to optimal levels could help counter each of those conditions. But in cancer especially, where the disease's biology varies by tumor type and stage, "it is not a simple 'more NAD+ is better' story," he cautioned, "and I'd resist it being written as one."

For decision-makers, the practical read is a mechanism, not a molecule to sell. The study identifies a specific, testable link between cellular metabolism and immune memory, the kind of finding that reshapes how drug developers design immuno-modulating therapies and how investors underwrite them. It also reframes aging: if NAD+ availability gates the innate immune system's readiness, then metabolic decline is not just an energy story, it is an immune story. The obvious next questions are whether the mouse findings replicate in human cohorts, whether NAD+ status can serve as a biomarker for who responds to trained-immunity-based interventions, and whether modulating the pathway helps or hurts in cancer, where the answer likely depends on the tumor.

What the paper does not do is hand anyone a supplement strategy. It was conducted in mouse cells, live mice and a limited set of human cells, and its claims about aging, cancer and Alzheimer's remain hypotheses. The value right now is the explanation itself: a mark that should have vanished survives because a metabolic molecule quietly disables the enzyme sent to erase it. That is a small mechanism with a large blast radius, and it is worth watching which lab confirms it next.

Executive ActionsLocked

This story's Key Insights and Take-aways are locked.

Create a free account to unlock Executive Actions for one credit.

Register to Unlock

Always free for Executives Club members. Join the Club

More in Science